Project Grant R41DK143771
Award Date 7/1/26
Completion Date 6/30/27
Dollars Obligated $350K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Stony Brook, NY 11790, USA
Similar Awards
- Federal Project Grant Award Summary HTIC, Inc. received a $310,438 Phase 1 Small Business Technology Transfer (STTR) award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 15, 2025, through September 14, 2026. The project deliverables focus on developing and validating a novel humanized monoclonal antibody (hCitH3-MAb) designed to inhibit excessive...
- Federal Grant Award Summary Cytoagents Inc. received a $1.31 million Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on September 22, 2025, with completion targeted for August 31, 2027. The award supports the development of CTO1681, an orally available pharmaceutical compound designed to prevent and mitigate cytokine release syndrome (CRS) in multiple myeloma patients undergoing chimeric antigen receptor (CAR) T-cell therapy....
- Federal Grant Award Summary In Vivo Microsystems Technologies, LLC received a $2.04 million Phase 2 Small Business Innovation Research (SBIR) Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). Awarded on September 19, 2025, with completion targeted for August 31, 2027, this grant supports a multi-center clinical study to advance a novel near-infrared (NIR)...
- Federal Project Grant Award Summary Syntis Bio Inc. received a $324,984 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) effective August 1, 2025, through July 31, 2027. The company is developing an oral therapeutic platform to treat homocystinuria (HCU), a rare metabolic disorder caused by cystathionine-β-synthase enzyme deficiency. The core...
- Federal Grant Award Summary Mucommune LLC received a $719,216 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) awarded September 15, 2025, with completion targeted for August 31, 2027. The project involves the development and evaluation of MM010, a reformulated pegloticase biobetter designed to safely reduce uric acid levels and suppress fructose-induced obesity and...
- Federal Grant Award Summary Halomine Inc. (doing business as Avantguard) received a $348,150 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on September 15, 2025, with a completion date of September 14, 2026. The award supports the development and optimization of Avantamine, a stabilized, chloramine-based topical antiseptic designed to treat infected...
- Federal Grant Award Summary Eldec Pharmaceuticals, Inc. received a $560,244 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on September 12, 2025, with a completion date of June 30, 2028. The research focuses on the development and testing of ELD607, a novel peptide therapeutic antagonist designed to inhibit the ORAI1 calcium channel. This therapeutic...
- Federal Grant Award Summary Fred Hutchinson Cancer Center received a $132,000 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective May 20, 2026, with a completion date of March 31, 2028. The award funds fundamental biomedical research investigating stromal regulation of hematopoiesis through syndecan-2 expression in bone marrow mesenchymal...
- Federal Grant Award Summary Biotherapeutics, Inc. received a $628,726 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 13, 2025, with completion targeted for January 31, 2026. The grant funds Phase I Small Business Innovation Research (SBIR) activities to develop a novel, oral, host-targeted therapeutic candidate designed to treat patients with concomitant...
- Federal Grant Award Summary Fesariustherapeutics Inc. received a $349,892 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025, through August 31, 2027. The award supports development of DermisphereShield, an antimicrobial dermal regeneration template designed to address complex wound healing challenges in contaminated environments. The product targets critical clinical...